GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Annesofie Faurschou, MD PhD
- Phone Number: +45 39773977
Study Locations
-
-
-
Hellerup, Denmark, 2900
- Recruiting
- Gentofte Hospital
-
Contact:
- Lone Skov, Prof
- Phone Number: +45 39773977
- Email: losk@geh.regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
4.3 Inclusion Criteria
- Caucasians above 18 years of age
- Plaque psoriasis
- PASI score >10
- No treatment or stable treatment of psoriasis during at least 3 months before inclusion
- Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
- Normal blood pressure
- Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life) 4.4 Exclusion Criteria
- Psoriasis arthritis
- Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%
- Type 1 diabetes
- Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
- Heart failure, NYHA class III-IV
- Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
- Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)
- Anaemia
- Acute or chronic pancreatitis
- Struma or thyroid cancer
- Pregnancy or breast feeding
- Inability to complete the study
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
The placebo pens contain saline and are administered in the same way and volume as Victoza.
The placebo pens are specially prepared for this study and will be used in the study only
|
|
Active Comparator: Psoriasis
|
Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15).
Commercial pens will be used and the information given in the packaging will be applicable.
The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period.
The injection is administered once daily in the morning.
The maximal plasma concentration is reached 8-12 hours after subcutaneous injection.
The half-life in plasma is approximately 13 hours.
The duration of effect is 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in PASI and DLQI
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GLP1-PSO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.